Compare Citius Pharmaceuticals Inc (CTXR) vs Flux Power Holdings Inc (FLUX) Price & Performance

CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.

Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.

FLUX trades at $0.7304, down 5.94% in the last session, with a bearish technical signal from moving averages. The company reported mixed quarterly results, missing Q3 2026 EPS estimates but beating in Q4 2025. Revenue declined from $66M in 2025 to $51M in 2026, with negative net income margins persisting. Recent developments include the launch of SkyEMS 3.0 AI-powered fleet management software and new executive appointments aimed at growth acceleration.

Despite unanimous analyst buy ratings, FLUX faces significant profitability challenges with negative ROE and ROA. The stock's primary investment opportunity lies in its clean energy technology positioning and strong analyst support, but risks include ongoing losses, revenue contraction, and competitive pressures in the energy storage market that could limit near-term upside potential.